SLC5A2 and type 2 diabetes mellitus: Although new T2DM therapies, including sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have demonstrated cardiovascular benefits (6, 7), it is still crucial to identify and manage T2DM patients who are at risk of developing MI at an early stage.